Patrick Lamy Sells 5,000 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Patrick Lamy sold 5,000 shares of Akero Therapeutics stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $57.03, for a total transaction of $285,150.00. Following the completion of the transaction, the vice president now owns 33,492 shares of the company’s stock, valued at $1,910,048.76. This represents a 12.99 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Patrick Lamy also recently made the following trade(s):

• On Monday, December 16th, Patrick Lamy sold 1,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $29.13, for a total transaction of $29,130.00.
• On Tuesday, December 10th, Patrick Lamy sold 925 shares of Akero Therapeutics stock. The shares were sold at an average price of $30.79, for a total value of $28,480.75.

Akero Therapeutics Trading Up 2.5 %

NASDAQ AKRO opened at $55.36 on Friday. The firm’s fifty day moving average is $29.78 and its two-hundred day moving average is $28.69. Akero Therapeutics, Inc. has a one year low of $15.32 and a one year high of $58.40. The company has a debt-to-equity ratio of 0.05, a quick ratio of 17.25 and a current ratio of 17.25. The firm has a market cap of $3.86 billion, a PE ratio of -14.76 and a beta of -0.19.

Akero Therapeutics (NASDAQ:AKRO) last issued its quarterly earnings results on Friday, November 8th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.15). Analysts expect that Akero Therapeutics, Inc. will post -3.96 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. grew its position in Akero Therapeutics by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,511 shares of the company’s stock valued at $71,000 after buying an additional 446 shares during the last quarter. Eastern Bank purchased a new stake in shares of Akero Therapeutics in the third quarter valued at about $100,000. Summit Financial Wealth Advisors LLC purchased a new position in Akero Therapeutics during the third quarter worth about $205,000. Victory Capital Management Inc. acquired a new stake in Akero Therapeutics in the third quarter valued at about $211,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in Akero Therapeutics in the 3rd quarter valued at approximately $265,000.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. HC Wainwright increased their price objective on Akero Therapeutics from $50.00 to $72.00 and gave the company a “buy” rating in a report on Monday. Bank of America upgraded shares of Akero Therapeutics from a “neutral” rating to a “buy” rating and increased their price target for the company from $35.00 to $63.00 in a research note on Thursday. Canaccord Genuity Group boosted their price objective on shares of Akero Therapeutics from $56.00 to $73.00 and gave the stock a “buy” rating in a research report on Tuesday. Citigroup increased their target price on shares of Akero Therapeutics from $65.00 to $80.00 and gave the company a “buy” rating in a research report on Tuesday. Finally, Morgan Stanley upped their price objective on shares of Akero Therapeutics from $46.00 to $96.00 and gave the company an “overweight” rating in a research note on Tuesday. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $66.29.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.